Search Results

Displaying Results 1-2 of 2 "'RNXT'"
Making a selection with these dropdown will cause content on this page to change. News search result will update as each option is selected.
$668B Oncology Surge: 5 Platforms Cracking the Code on GI Tumors

Jan 30, 2026, 10:19 ET $668B Oncology Surge: 5 Platforms Cracking the Code on GI Tumors

ONCY), Pfizer (NYSE: PFE), Verastem Oncology (NASDAQ: VSTM), Perspective Therapeutics (NYSE-A: CATX), and RenovoRx (NASDAQ: RNXT) directly at the intersection of pivotal execution and breakthrough immunotherapy. 

More news about: USA News Group

Natural Killer Cell Therapies Lead $254B Immunotherapy Market Transformation

Oct 17, 2025, 09:50 ET Natural Killer Cell Therapies Lead $254B Immunotherapy Market Transformation

evaluating EVX-01 in combination with MSD's anti-PD-1 therapy KEYTRUDA. RenovoRx, Inc. (NASDAQ: RNXT) has successfully completed the

More news about: Equity Insider

Making a selection with these dropdown will cause content on this page to change. News search result will update as each option is selected.